ConductScience.org, home

Paper19756352

Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Maekawa S and 1 other. J Gastroenterol, 2009. Cited by 30 papers, by iCite.

Cite this record

ConductScience Library. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. Papers, record 19756352. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19756352

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.
PubMed
Journal
J Gastroenterol
PubMed
Year
2009
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
30
iCite
Relative citation ratio, by iCite
0.76
iCite
Revised in PubMed
2021-10-20
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Maekawa SShinya
2Enomoto NNobuyuki

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
HepacivirusMajor topic
Hepatitis C, ChronicMajor topic
Interferon-alphaMajor topic
RibavirinMajor topic
Drug Therapy, Combination
Genetic Variation
Genotype
Humans
Interferon alpha-2
Polyethylene Glycols
Recombinant Proteins
Treatment Outcome
Viral Load
Virulence Factors

Source PubMed

Download CSV of topics

References83

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19143277Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein.Virology1997https://conductscience.org/library/papers/9143277PubMed
218069766Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.World J Gastroenterol2007https://conductscience.org/library/papers/18069766PubMed
31325713Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability.Virology1992https://conductscience.org/library/papers/1325713PubMed
415888797Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.Gut2005https://conductscience.org/library/papers/15888797PubMed
517446688Prediction of efficient virological response to pegylated interferon/ribavirin combination therapy by NS5A sequences of hepatitis C virus and anti-NS5A antibodies in pre-treatment sera.Microbiol Immunol2007https://conductscience.org/library/papers/17446688PubMed
616958669Causes and consequences of mitochondrial reactive oxygen species generation in hepatitis C.J Gastroenterol Hepatol2006https://conductscience.org/library/papers/16958669PubMed
716024941Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.Intervirology2005https://conductscience.org/library/papers/16024941PubMed
810669323Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response.J Infect Dis2000https://conductscience.org/library/papers/10669323PubMed
914748063Lack of clinical significance of variability in the internal ribosome entry site of hepatitis C virus.J Med Virol2004https://conductscience.org/library/papers/14748063PubMed
1010406177Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy.J Hepatol1999https://conductscience.org/library/papers/10406177PubMed
119334922Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b.J Med Virol1997https://conductscience.org/library/papers/9334922PubMed
1216279899Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.Am J Gastroenterol2005https://conductscience.org/library/papers/16279899PubMed
1311773402Detection of a novel unglycosylated form of hepatitis C virus E2 envelope protein that is located in the cytosol and interacts with PKR.J Virol2002https://conductscience.org/library/papers/11773402PubMed
1418448540Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.J Virol2008https://conductscience.org/library/papers/18448540PubMed
1517973647
Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.
Aliment Pharmacol Ther2008https://conductscience.org/library/papers/17973647PubMed
1616098627Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.J Hepatol2005https://conductscience.org/library/papers/16098627PubMed
1717040112Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.Drugs2006https://conductscience.org/library/papers/17040112PubMed
189634077Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity.J Gen Virol1998https://conductscience.org/library/papers/9634077PubMed
199247477Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa.Gastroenterology1997https://conductscience.org/library/papers/9247477PubMed
2019235866
Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy.
J Med Virol2009https://conductscience.org/library/papers/19235866PubMed

See all 83 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.

PMIDTitleJournalYearIn PapersSource
31534084Generation Gap for Screening and Treatment of Hepatitis C Virus in Saga Prefecture, Japan: An Administrative Database Study of 35,625 Subjects.Intern Med2020https://conductscience.org/library/papers/31534084PubMed
25780333A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data.Evol Bioinform Online2015https://conductscience.org/library/papers/25780333PubMed
25578520Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use.Cytokine Growth Factor Rev2015https://conductscience.org/library/papers/25578520PubMed
24708767Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy.J Transl Med2014https://conductscience.org/library/papers/24708767PubMed
23429668Clinical impact of hepatitis B and C virus envelope glycoproteins.World J Gastroenterol2013https://conductscience.org/library/papers/23429668PubMed
23314745Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.Eur J Clin Microbiol Infect Dis2013https://conductscience.org/library/papers/23314745PubMed
23193392Baseline serum cholesterol is associated with a response to pegylated interferon alfa-2b and ribavirin therapy for chronic hepatitis C genotype 2.Gastroenterol Res Pract2012https://conductscience.org/library/papers/23193392PubMed
23181537Significance of a reduction in HCV RNA levels at 4 and 12 weeks in patients infected with HCV genotype 1b for the prediction of the outcome of combination therapy with peginterferon and ribavirin.BMC Infect Dis2012https://conductscience.org/library/papers/23181537PubMed
22993188NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.J Clin Microbiol2012https://conductscience.org/library/papers/22993188PubMed
21484111Differences in the factors associated with serum viral load between genotypes 1 and 2 in patients with chronic hepatitis C.Hepatol Int2013https://conductscience.org/library/papers/21484111PubMed
20927636
High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b.
J Gastroenterol2011https://conductscience.org/library/papers/20927636PubMed
20805953Very-Low-Dose Pegylated Interferon a2a Plus Ribavirin Therapy for Advanced Liver Cirrhosis Type C: A Possible Therapeutic Alternative without Splenic Intervention.Case Rep Gastroenterol2010https://conductscience.org/library/papers/20805953PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19756352

GET https://conductscience.org/api/papers/v1/19756352/references?page=2